HNWAG
STRO icon

High Net Worth Advisory Group’s Sutro Biopharma STRO Stock Holding History

High Net Worth Advisory Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$8K – 719
2022
Q1 		$8K Buy
+100
New +$9.52K ﹤0.01% 556

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

High Net Worth Advisory Group's STRO Position: Q2 2022 in Review

High Net Worth Advisory Group sold out of Sutro Biopharma (STRO) in Q2 2022, closing a stake of 100 shares — an estimated $8K sold.

High Net Worth Advisory Group first reported a position in STRO in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 114 funds tracked by Wall St. Rank hold STRO as of Q2 2022.

  • High Net Worth Advisory Group reported no remaining Sutro Biopharma position as of Q2 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 100 Sutro Biopharma shares in Q2 2022, an estimated $8K.
  • High Net Worth Advisory Group first reported a position in Sutro Biopharma in Q1 2022 and held it in 1 quarter.
  • High Net Worth Advisory Group's Sutro Biopharma position peaked at $8K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2022.

Based on High Net Worth Advisory Group's 13F filing for Q2 2022, filed 10 Aug 2022.